Co. Uses Protein Modulation to Treat Cancer
Source: Streetwise Reports  (4/9/22)
Nurix Therapeutics Inc. shares traded 13% higher after the company reported Q1/22 financial results and released an outline for two poster presentations that will be submitted at the American Association for Cancer Research Annual Meeting this weekend. More >

FDA Approves Bipolar and Schizophrenia Drug
Source: Streetwise Reports  (4/6/22)
BioXcel Therapeutics Inc. reported that the U.S. FDA has approved its IGALMIâ„¢ (dexmedetomidine) Sublingual Film for use in acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. More >

Can We Make a Pill to End the Pandemic?
Source: Vision and Value  (4/4/22)
Vision and Value discusses the state of the virus and big pharma's race to slow the death rate as well as the spread of the pandemic — and what it means for investors. More >

Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial
Source: Streetwise Reports  (4/2/22)
NGM Biopharmaceuticals Inc. shares rose 14.75% after the company reported it dosed the first group of patients in its Phase 1/1b clinical trial of NGM831 for use in treating advanced solid tumors. More >

Chen's Top Picks for Q2 2022
Source: Streetwise Reports  (4/1/22)
Asset manager and contributing writer Chen Lin looks to the biotechnology and mining sectors for his top second quarter picks. More >

Biotech Co. Posts Notable PFS Gains in Ph. 3 Cancer Trial
Source: Streetwise Reports  (3/31/22)
Clovis Oncology Inc. shares traded 36% higher after the company reported that in the Phase 3 ATHENA-MONO clinical study its Rubraca® (Rucaparib) was shown to significantly improve progression-free survival in women diagnosed with ovarian cancer. More >

Biotech Firm's Shares Double on $6B Deal
Source: Streetwise Reports  (3/29/22)
Shares of IGM Biosciences Inc. traded 97% higher after the company reported FY/21 financial results and announced it entered into a collaborative partnership with Sanofi SA to develop six separate IgM antibody agonists for three oncology and three autoimmune/inflammation targets. More >

Biotech Co. Posts Positive Data in Ph. 1/2 Kidney Cancer Trial
Source: Streetwise Reports  (3/23/22)
Shares of 4D Pharma Plc. traded 28% higher after the company reported positive interim results from its Phase 1/2 study of its MRx0518 in combination with Merck & Co.'s KEYTRUDA® (pembrolizumab) for use in treating renal cell carcinoma. More >

Biotech Co. Gets $2M Grant for Parkinson's Treatment
Source: Streetwise Reports  (3/22/22)
Shares of SQZ Biotechnologies Co. traded 17% higher after the company reported that it has been awarded a $2 million grant from the NIH to develop a new cell replacement therapy for use in treating Parkinson's disease. More >

Co. Awaits FDA Approval of Drug, Prepares for Launch
  (3/21/22)
The biopharma's executive team is managing both time and opex spending well, noted an Oppenheimer report. More >

Drug Co. Gets PDUFA Date for TKI
  (3/20/22)
"We expect poziotinib approval in late 2022 with sales of $21.9 million this year," noted an H.C. Wainwright & Co. report. More >

Pharma Co. Gains FDA Approval for Epilepsy Seizure Drug
Source: Streetwise Reports  (3/19/22)
Shares of Marinus Pharmaceuticals Inc. jumped 16.4% higher near the end of trading today after the company reported that the U.S. FDA granted approval for its ZTALMY® (ganaxolone) in treating a rare type of genetic epilepsy called CDKL5 deficiency disorder. More >

Catalyst Could Push Pharma to Break Out
Source: Michael Sheikh  (3/18/22)
This pharmaceutical company is trading well below its cash value and is on the cusp of a potentially significant catalyst, one analyst says. More >

Biopharma Co. Enjoys Gains From Kidney Cancer Drug
Source: Streetwise Reports  (3/14/22)
Shares of this pharmaceuticals co. traded 22% higher after the company reported Q4/21 and FY/21 financial results that included a 17% sequential gain in net revenue from sales of its FOTIVDA® (tivozanib), which has been approved by the U.S. FDA for treating adults with relapsed or refractory advanced renal cell carcinoma (RCC). More >

License Revenues Kick in for Biopharma Co.
Source: Streetwise Reports  (3/12/22)
Shares of Clearside Biomedical Inc. traded 42% higher after the company reported Q4/21 and FY/21 financial results and provided an update regarding positive developments at the company including the receipt of over $20 million in milestone payments from its commercial development partner. More >

Co.'s Catalyst Rich 2022 Includes NDA, MAA Filings
  (3/10/22)
An Oppenheimer report notes that this pharmaceutical company is working to expand the approved uses of its lead drug candidate, and numerous catalysts involving Empaveli are expected this year. More >

Biotech Firm Should Increase Sales by 20% This Year
  (3/10/22)
This immunotherapy company's outlook for 2022 is positive with expected growth in overall product sales and progress on the clinical front, noted an H.C. Wainwright & Co. report. More >

Pharma Co. Shares Get a Bang from FDA Orphan Drug Approval
Source: Streetwise Reports  (3/9/22)
Shares of C4 Therapeutics Inc. traded 16% higher after the biopharma company reported that the U.S. FDA granted Orphan Drug approval status for its CFT8634 for use in treating soft tissue sarcoma. More >

This Year Should Be Catalyst Rich for Oncology Pharma Co.
  (3/1/22)
An outperform-rated biopharma, which has a robust year of significant events ahead, is trading now at a significant discount, noted a Wedbush report. More >

Biotech to Take Novel Cancer Drug to Market in H1/22
Source: Streetwise Reports  (2/28/22)
This biotech company is commercializing its lead drug candidate, Kimmtrak, has a catalyst-rich 2022, and has various clinical-stage drugs for cancers and autoimmune and infectious diseases. More >

Super Computers Create Powerful Drugs for Alzheimer's
Source: Streetwise Reports  (2/25/22)
A promising biotech company is finding new ways to treat neurodegenerative diseases by focusing on misfolded proteins. More >

Pharma Co. Posts 364% YOY Revenue Increase in Q421
Source: Streetwise Reports  (2/25/22)
Aerie Pharmaceuticals Inc. shares traded 30% higher after the ophthalmology-focused pharmaceutical company reported Q4/21 and FY/21 financial results and announced the appointment of a new Chief Medical Officer. More >

Pharma Co. Decreases BMI by 14.3% in Obesity Trial
Source: Streetwise Reports  (2/18/22)
Shares of this pharmaceutical company traded 16% higher after it reported positive interim data from its long-term extension study of a treatment for obesity and hyperphagia in patients with Bardet-Biedl Syndrome (BBS). More >

Pain Mgt. Co. Makes $604M Bid for BioDelivery Sciences
  (2/14/22)
Shares of BioDelivery Sciences International Inc. traded 52% higher after the company reported that it agreed to be acquired by Collegium Pharmaceutical Inc. in an all-cash deal for $5.60 per share. More >

Canadian Hedge Fund CIO Talks Top 2022 Prospects
Source: Streetwise Reports  (2/9/22)
AlphaNorth Asset Management was recently recognized with multiple performance awards at the 2021 Alternative IQ Canadian Hedge Fund Awards. The AlphaNorth Partners Fund won first place for its five-year annualized return gaining 40.35% for the period. The fund also placed second for its three-year return and third for its one-year return. Streetwise Reports sat down with CIO Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022. More >